Low molecular weight heparin and its preparation method

A low-molecular-weight heparin and average molecular weight technology, applied in the field of low-molecular-weight heparin and its preparation, can solve the problem of low bleeding and achieve the effect of improving the therapeutic index

Inactive Publication Date: 2006-12-20
上海复旦张江生物医药股份有限公司
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The average molecular weight of unfractionated heparin is 12000-15000, the anti-Xa activity is the same as the anti-IIa activity, while the average molecular weight of LMWH is 4000-6500, and the anti-Xa / anti-IIa is generally 1.5-4. Compared with unfractionated heparin, it has more selective anti- Thromboactive and low bleeding risk, but still contains a considerable proportion of high molecular weight components

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Low molecular weight heparin and its preparation method
  • Low molecular weight heparin and its preparation method
  • Low molecular weight heparin and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1, the preparation of low molecular weight heparin

[0072] Add 40g of heparin and 2000ml of distilled water into a 5000ml beaker until the heparin is completely dissolved; at 25°C, add 36% acetic acid to adjust the pH to 3.20. 320 ml of 0.7% sodium nitrite solution was added at one time, and the reaction was stirred at room temperature for 3.0 hours.

[0073] At the end of the reaction, use 4 mol / L sodium hydroxide to terminate the reaction (pH>4.00), and continue to use 4 mol / L sodium hydroxide to adjust the pH=10.0.

[0074] 0.8 g of sodium borohydride was added, and the reaction was stirred at room temperature for 18 hours for reduction. Use hydrochloric acid to adjust pH=4.00 to destroy excess sodium borohydride; then use 4mol / L sodium hydroxide to adjust pH=7.00. Store at less than 10°C. Add 40% v / v of 95% ethanol less than 10°C under the condition of stirring, stir while adding, and stand still under the condition of less th...

Embodiment 2

[0077] Embodiment 2, molecular weight analysis of low molecular weight heparin

[0078] The chromatograph selects HP 1100 high-performance liquid chromatography (DAD, RI detector), and the chromatographic column is TSK GELG2000SWXL, 7.8mmID*30cm, 5 μ m, detection wavelength: 234nm, mobile phase: with 2.84% (W / V) sodium sulfate solution Adjust pH to 5.0 with 1mol / L sulfuric acid, column pressure: 35-40kg, flow rate: 0.5ml / min.

[0079] Samples, standard substances and reference substances were prepared into 10mg / ml solution with mobile phase, and injected for analysis.

[0080] (1) System calibration: Inject 25 μl of standard solution, detect using a differential detector (RI) sequentially connected to a UV spectrophotometer with a measuring wavelength of 234 nm, and connect UV to the output end of the chromatographic column, and RI to UV output terminal. The time difference between the two detectors must be accurately measured so that the chromatogra...

Embodiment 3

[0085] Embodiment 3, anti-Xa factor potency determination

[0086] Preparation of the standard solution: the standard solution is diluted with tris-hydrochloric acid buffer (pH7.4) to make it contain 0.02, 0.05, 0.1, 0.15, 0.2 anti-factor Xa international units per 1 ml liquid.

[0087] Preparation of sample solution: the low-molecular-weight heparin prepared in Example 1 was dissolved in physiological saline and diluted to 0.1 mg / ml. Dilute 60 times with tris-hydrochloric acid buffer (pH7.4). (The anti-factor Xa titer of the estimated sample is 60IU / mg, and it is prepared into a sample solution containing about 0.1 international units of anti-factor Xa in every 1 milliliter.)

[0088] Take a small test tube, add 50 μl PURIFIED ATIII solution and 50 μl standard solution of each dilution, mix well, incubate in a 37°C incubator for 1 minute, add 100 μl Xa factor solution, mix well, incubate in a 37°C incubator for 1 minute, add 250 μl Chromogenic subs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

This invention discloses a low molecular heparin by decomposing natural heparin with nitrous acid, with average molecular weight between 2100Da and 2700Da, and 90% of the total component between 1500Da and 5400Da. The low molecular heparin of this invention has a low activity of anti-IIa factor, and the activity ratio of anti-Xa factor/anti-IIa factor is over 20, which greatly decreases the bleeding-out possibility. This invention also discloses the method for making the low molecular heparin, comprising procedures of nitrous acid decomposition, sodium borohydride reduction, and ethanol precipitation, with high yield.

Description

technical field [0001] The invention relates to a heparin product and a preparation method thereof, in particular to a low molecular weight heparin and a preparation method thereof. Background technique [0002] Thromboembolic disease is one of the serious threats faced by human beings at present. It has a relatively high morbidity and mortality and is a disease that seriously endangers human health, such as coronary heart disease, myocardial infarction, deep vein thrombosis (DVT), cerebral embolism, etc. , Pulmonary embolism (PE), etc. In addition, thrombosis is an important pathological process involved in the pathogenesis of many diseases, such as diabetic small vessel disease, glomerulonephritis, exacerbation of local lesions in severe burns, pregnancy-induced hypertension syndrome, retinal vein thrombosis, various Causes of disseminated intravascular coagulation, etc. Therefore, the prevention and treatment of thrombosis is of great significance to improve the quality...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C08B37/10
Inventor 王作鹏张立红
Owner 上海复旦张江生物医药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap